Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma.

Neidler S, Kruspig B, Hewit K, Monteverde T, Gyuraszova K, Braun A, Clark W, James D, Hedley A, Nieswandt B, Shanks E, Dick C, Murphy DJ.

Cancers (Basel). 2019 Apr 29;11(5). pii: E600. doi: 10.3390/cancers11050600.

2.

Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress.

Port J, Muthalagu N, Raja M, Ceteci F, Monteverde T, Kruspig B, Hedley A, Kalna G, Lilla S, Neilson L, Brucoli M, Gyuraszova K, Tait-Mulder J, Mezna M, Svambaryte S, Bryson A, Sumpton D, McVie A, Nixon C, Drysdale M, Esumi H, Murray GI, Sansom OJ, Zanivan SR, Murphy DJ.

Cancer Discov. 2018 May;8(5):632-647. doi: 10.1158/2159-8290.CD-17-0533. Epub 2018 Mar 2.

3.

Correction: Tudor staphylococcal nuclease drives chemoresistance of non-small cell lung carcinoma cells by regulating S100A11.

Zagryazhskaya A, Surova O, Akbar NS, Allavena G, Gyuraszova K, Zborovskaya IB, Tchevkina EM, Zhivotovsky B.

Oncotarget. 2016 Apr 19;7(16):22970. doi: 10.18632/oncotarget.8805. No abstract available.

4.

YM155, a small molecule inhibitor of survivin expression, sensitizes cancer cells to hypericin-mediated photodynamic therapy.

Gyurászová K, Mikeš J, Halaburková A, Jendželovský R, Fedoročko P.

Photochem Photobiol Sci. 2016 Jun 8;15(6):812-21. doi: 10.1039/c5pp00438a. Epub 2016 May 31.

PMID:
27241169
5.

Cell death in cancer therapy of lung adenocarcinoma.

Zagryazhskaya A, Gyuraszova K, Zhivotovsky B.

Int J Dev Biol. 2015;59(1-3):119-29. doi: 10.1387/ijdb.150044bz. Review.

6.

Tudor staphylococcal nuclease drives chemoresistance of non-small cell lung carcinoma cells by regulating S100A11.

Zagryazhskaya A, Surova O, Akbar NS, Allavena G, Gyuraszova K, Zborovskaya IB, Tchevkina EM, Zhivotovsky B.

Oncotarget. 2015 May 20;6(14):12156-73. Erratum in: Oncotarget. 2016 Apr 19;7(16):22970.

7.

Conjunction of glutathione level, NAD(P)H/FAD redox status and hypericin content as a potential factor affecting colon cancer cell resistance to photodynamic therapy with hypericin.

Mikešová L, Mikeš J, Kovaľ J, Gyurászová K, Culka L, Vargová J, Valeková B, Fedoročko P.

Photodiagnosis Photodyn Ther. 2013 Dec;10(4):470-83. doi: 10.1016/j.pdpdt.2013.04.003. Epub 2013 May 25.

PMID:
24284100

Supplemental Content

Loading ...
Support Center